Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF

Cancer Cell

Volumn 23, Issue 3, 2013, Pages 302-315

  Haq, Rizwan ^a,b   Shoag, Jonathan ^c   Andreu Perez, Pedro ^b   Yokoyama, Satoru ^b,d   Edelman, Hannah ^b   Rowe, Glenn C ^c   Frederick, Dennie T ^b   Hurley, Aeron D ^e   Nellore, Abhinav ^f   Kung, Andrew L ^g   Wargo, Jennifer A ^b   Song, Jun S ^f   Fisher, David E ^a,b   Arany, Zolt ^c   Widlund, Hans R ^e  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TOYAMA   (Japan)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PGC1 ALPHA; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOENERGY; BIOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; MELANOMA CELL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 84876436850     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.02.003     Document Type: Article

References (78)

1. Arany Z., Foo S.Y., Ma Y., Ruas J.L., Bommi-Reddy A., Girnun G., Cooper M., Laznik D., Chinsomboon J., Rangwala S.M., et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008, 451:1008-1012.
2. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N.C., Nakano K., Bartrons R., Gottlieb E., Vousden K.H. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
3. Bertolotto C., Lesueur F., Giuliano S., Strub T., de Lichy M., Bille K., Dessen P., d'Hayer B., Mohamdi H., Remenieras A., et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011, 480:94-98. French Familial Melanoma Study Group.
4. Bhalla K., Hwang B.J., Dewi R.E., Ou L., Twaddel W., Fang H.B., Vafai S.B., Vazquez F., Puigserver P., Boros L., Girnun G.D. PGC1α promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res. 2011, 71:6888-6898.
5. Board R.E., Ellison G., Orr M.C.M., Kemsley K.R., McWalter G., Blockley L.Y., Dearden S.P., Morris C., Ranson M., Cantarini M.V., et al. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br. J. Cancer 2009, 101:1724-1730.
6. Bogunovic D., O'Neill D.W., Belitskaya-Levy I., Vacic V., Yu Y.-L., Adams S., Darvishian F., Berman R., Shapiro R., Pavlick A.C., et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl. Acad. Sci. USA 2009, 106:20429-20434.
7. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
8. Boni A., Cogdill A.P., Dang P., Udayakumar D., Njauw C.N.J., Sloss C.M., Ferrone C.R., Flaherty K.T., Lawrence D.P., Fisher D.E., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010, 70:5213-5219.
9. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., Lee C.T., Lopaschuk G.D., Puttagunta L., Bonnet S., et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
10. Carreira S., Goodall J., Denat L., Rodriguez M., Nuciforo P., Hoek K.S., Testori A., Larue L., Goding C.R. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006, 20:3426-3439.
11. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364:2507-2516. BRIM-3 Study Group.
12. Chinsomboon J., Ruas J., Gupta R.K., Thom R., Shoag J., Rowe G.C., Sawada N., Raghuram S., Arany Z. The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle. Proc. Natl. Acad. Sci. USA 2009, 106:21401-21406.
13. Colombi M., Molle K.D., Benjamin D., Rattenbacher-Kiser K., Schaefer C., Betz C., Thiemeyer A., Regenass U., Hall M.N., Moroni C. Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction. Oncogene 2011, 30:1551-1565.
14. Cui R., Widlund H.R., Feige E., Lin J.Y., Wilensky D.L., Igras V.E., D'Orazio J., Fung C.Y., Schanbacher C.F., Granter S.R., Fisher D.E. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007, 128:853-864.
15. Curtin J.A., Fridlyand J., Kageshita T., Patel H.N., Busam K.J., Kutzner H., Cho K.-H., Aiba S., Bröcker E.B., LeBoit P.E., et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005, 353:2135-2147.
16. Cutting W.C., Tainter M.L. Metabolic actions of dinitrophenol with the use of balanced and unbalanced diets. J. Am. Med. Assoc. 1933, 101. 2099-2012.
17. Dang C.V. Links between metabolism and cancer. Genes Dev. 2012, 26:877-890.
18. Dankort D., Curley D.P., Cartlidge R.A., Nelson B., Karnezis A.N., Damsky W.E., You M.J., DePinho R.A., McMahon M., Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 2009, 41:544-552.
19. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
20. Dhomen N., Reis-Filho J.S., da Rocha Dias S., Hayward R., Savage K., Delmas V., Larue L., Pritchard C., Marais R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009, 15:294-303.
21. D'Orazio J.A., Nobuhisa T., Cui R., Arya M., Spry M., Wakamatsu K., Igras V., Kunisada T., Granter S.R., Nishimura E.K., et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 2006, 443:340-344.
22. *) mediates metabolic shift in breast cancer cells via the PGC-1β/ERRγ transcriptional pathway. Cell Metab. 2010, 12:352-361.
23. Fantin V.R., Leder P. Mitochondriotoxic compounds for cancer therapy. Oncogene 2006, 25:4787-4797.
24. Fantin V.R., St-Pierre J., Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9:425-434.
25. Finck B.N., Kelly D.P. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 2006, 116:615-622.
26. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363:809-819.
27. Garraway L.A., Widlund H.R., Rubin M.A., Getz G., Berger A.J., Ramaswamy S., Beroukhim R., Milner D.A., Granter S.R., Du J., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
28. Girnun G.D. The diverse role of the PPARγ coactivator 1 family of transcriptional coactivators in cancer. Semin. Cell Dev. Biol. 2012, 23:381-388.
29. Goding C.R. Commentary. A picture of Mitf in melanoma immortality. Oncogene 2011, 30:2304-2306.
30. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
31. Greger J.G., Eastman S.D., Zhang V., Bleam M.R., Hughes A.M., Smitheman K.N., Dickerson S.H., Laquerre S.G., Liu L., Gilmer T.M. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 2012, 11:909-920.
32. Handschin C. The biology of PGC-1α and its therapeutic potential. Trends Pharmacol. Sci. 2009, 30:322-329.
33. Handschin C., Rhee J., Lin J., Tarr P.T., Spiegelman B.M. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proc. Natl. Acad. Sci. USA 2003, 100:7111-7116.
34. Haq R., Fisher D.E. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J. Clin. Oncol. 2011, 29:3474-3482.
35. Hemesath T.J., Price E.R., Takemoto C., Badalian T., Fisher D.E. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 1998, 391:298-301.
36. Herzig S., Long F., Jhala U.S., Hedrick S., Quinn R., Bauer A., Rudolph D., Schutz G., Yoon C., Puigserver P., et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 2001, 413:179-183.
37. Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003, 63:5198-5202.
38. Hoeflich K.P., Gray D.C., Eby M.T., Tien J.Y., Wong L., Bower J., Gogineni A., Zha J., Cole M.J., Stern H.M., et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 2006, 66:999-1006.
39. Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 2006, 19:290-302.
40. Joseph E.W., Pratilas C.A., Poulikakos P.I., Tadi M., Wang W., Taylor B.S., Halilovic E., Persaud Y., Xing F., Viale A., et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 2010, 107:14903-14908.
41. Karasarides M., Chiloeches A., Hayward R., Niculescu-Duvaz D., Scanlon I., Friedlos F., Ogilvie L., Hedley D., Martin J., Marshall C.J., et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298.
42. Kelly D.P., Scarpulla R.C. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 2004, 18:357-368.
43. Klimcakova E., Chénard V., McGuirk S., Germain D., Avizonis D., Muller W.J., St-Pierre J. PGC-1α promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply. Cancer Res. 2012, 72:1538-1546.
44. Lehman J.J., Barger P.M., Kovacs A., Saffitz J.E., Medeiros D.M., Kelly D.P. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J. Clin. Invest. 2000, 106:847-856.
45. Leone T.C., Kelly D.P. Transcriptional control of cardiac fuel metabolism and mitochondrial function. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:175-182.
46. Li J., Song J.S., Bell R.J.A., Tran T.-N.T., Haq R., Liu H., Love K.T., Langer R., Anderson D.G., Larue L., Fisher D.E. YY1 regulates melanocyte development and function by cooperating with MITF. PLoS Genet. 2012, 8:e1002688.
47. Lin J., Wu H., Tarr P.T., Zhang C.-Y., Wu Z., Boss O., Michael L.F., Puigserver P., Isotani E., Olson E.N., et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002, 418:797-801.
48. Lin J., Handschin C., Spiegelman B.M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005, 1:361-370.
49. Lin J., Yang R., Tarr P.T., Wu P.-H., Handschin C., Li S., Yang W., Pei L., Uldry M., Tontonoz P., et al. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1β coactivation of SREBP. Cell 2005, 120:261-273.
50. Lin W.M., Baker A.C., Beroukhim R., Winckler W., Feng W., Marmion J.M., Laine E., Greulich H., Tseng H., Gates C., et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008, 68:664-673.
51. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., Hurley P.J., Bunz F., Hwang P.M. p53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
52. Miura S., Kai Y., Kamei Y., Ezaki O. Isoform-specific increases in murine skeletal muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) mRNA in response to beta2-adrenergic receptor activation and exercise. Endocrinology 2008, 149:4527-4533.
53. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehár J., Puigserver P., Carlsson E., Ridderstråle M., Laurila E., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34:267-273.
54. Poulikakos P.I., Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011, 19:11-15.
55. Pratilas C.A., Taylor B.S., Ye Q., Viale A., Sander C., Solit D.B., Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 2009, 106:4519-4524.
56. Prickett T.D., Agrawal N.S., Wei X., Yates K.E., Lin J.C., Wunderlich J.R., Cronin J.C., Cruz P., Rosenberg S.A., Samuels Y. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 2009, 41:1127-1132.
57. Sahin E., Colla S., Liesa M., Moslehi J., Müller F.L., Guo M., Cooper M., Kotton D., Fabian A.J., Walkey C., et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011, 470:359-365.
58. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012, 366:707-714.
59. Stark M.S., Woods S.L., Gartside M.G., Bonazzi V.F., Dutton-Regester K., Aoude L.G., Chow D., Sereduk C., Niemi N.M., Tang N., et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 2012, 44:165-169.
60. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
61. Tainter M.L., Cutting W.C., Stockton A.B. Use of dinitrophenol in nutritional disorders: a critical survey of clinical results. Am. J. Public Health Nations Health 1934, 24:1045-1053.
62. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 2008, 105:3041-3046.
63. Uldry M., Yang W., St-Pierre J., Lin J., Seale P., Spiegelman B.M. Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab. 2006, 3:333-341.
64. Vachtenheim J., Borovanský J. "Transcription physiology" of pigment formation in melanocytes: central role of MITF. Exp. Dermatol. 2010, 19:617-627.
65. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
66. Wan P.T.C., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867. Cancer Genome Project.
67. Wang X., Moraes C.T. Increases in mitochondrial biogenesis impair carcinogenesis at multiple levels. Mol. Oncol. 2011, 5:399-409.
68. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
69. Weinberg F., Hamanaka R., Wheaton W.W., Weinberg S., Joseph J., Lopez M., Kalyanaraman B., Mutlu G.M., Budinger G.R.S., Chandel N.S. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. USA 2010, 107:8788-8793.
70. Wellbrock C., Marais R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J. Cell Biol. 2005, 170:703-708.
71. Wellbrock C., Rana S., Paterson H., Pickersgill H., Brummelkamp T., Marais R. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 2008, 3:e2734.
72. Wise D.R., Thompson C.B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 2010, 35:427-433.
73. Wolfrum C., Stoffel M. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab. 2006, 3:99-110.
74. Wu Z., Puigserver P., Andersson U., Zhang C., Adelmant G., Mootha V., Troy A., Cinti S., Lowell B., Scarpulla R.C., Spiegelman B.M. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999, 98:115-124.
75. Wu M., Hemesath T.J., Takemoto C.M., Horstmann M.A., Wells A.G., Price E.R., Fisher D.Z., Fisher D.E. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 2000, 14:301-312.
76. Yokoyama S., Woods S.L., Boyle G.M., Aoude L.G., MacGregor S., Zismann V., Gartside M., Cust A.E., Haq R., Harland M., et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011, 480:99-103.
77. Yoon J.C., Puigserver P., Chen G., Donovan J., Wu Z., Rhee J., Adelmant G., Stafford J., Kahn C.R., Granner D.K., et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001, 413:131-138.
78. Yun J., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., Schmidt K., Willson J.K., Markowitz S., Zhou S., et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.